NCT02020512已完成4 期
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 87
- 主要终点
- Change From Baseline in Intraocular Pressure (IOP) in the Study Eye
研究概览
简要总结
This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of open-angle glaucoma or ocular hypertension
- •No use of Lumigan® in the past 3 months
排除标准
- •Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months
研究组 & 干预措施
0.03% Bimatoprost
Experimental
0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
干预措施: 0.03% Bimatoprost (Drug)
结局指标
主要结局
Change From Baseline in Intraocular Pressure (IOP) in the Study Eye
时间窗: Baseline, Week 5
IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
A Study of Bimatoprost 0.01% in the Clinical SettingGlaucoma, Primary Open AngleOcular HypertensionNCT01814761Allergan312
已完成
3 期
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT01830140Allergan466
已完成
4 期
Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash HypotrichosisHypotrichosisNCT00958035Allergan89
已完成
4 期
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%GlaucomaOcular HypertensionNCT00440011Allergan266
已完成
2 期
Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash ProminenceEyelash HypotrichosisNCT01064882Allergan104